Beta-blockers in the management of coronary artery disease: Are we on the verge of a new paradigm shift?

Recent Patents on Cardiovascular Drug Discovery

Volumn 9, Issue 1, 2014, Pages 11-21

  Elgendy, Islam Y ^a   Mahmoud, Ahmed ^a   Conti, Charles R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Beta blockers; Mortality; Myocardial infarction; Stable angina

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL; PARTIAL AGONIST; PROPRANOLOL; TIMOLOL; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DRUG SELECTIVITY; HEART EJECTION FRACTION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; PARTIAL AGONISM; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; VASODILATATION; CLINICAL PHARMACOLOGY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG ACTIVITY; FIBRINOLYTIC THERAPY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANGINA PECTORIS; ANGINA, STABLE; ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ANGINA PECTORIS; ANGINA, STABLE; ANIMALS; CORONARY ARTERY DISEASE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA;

EID: 85010682283     PISSN: 15748901     EISSN: 22123962     Source Type: Journal    
DOI: 10.2174/1574890109666140901144210     Document Type: Article

References (71)

1. [1] Hebb AR, Godwin TF, Gunn RW. A new beta adrenergic blocking agent, propranolol, in the treatment of angina pectoris. Can Med Assoc J 1968; 98:246-251.
2. [2] Prichard BN, Dickinson CJ, Alleyene GA, Hurst P, Hill ID, Rosenheim ML, et al. Effect of Pronethalol in Angina Pectoris. Br Med J 1963; 16: 1226-1229.
3. [3] Hamer J, Grandjean T, Melendez L, Sowton GE. Effect of Propranolol (Inderal) in Angina Pectoris: Preliminary Report. Br Med J 1964; 19: 720-723.
4. [4] Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature 2009; 459: 356-363.
5. [5] Kobilka BK. Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol Sci 2011; 32: 213-218.
6. [6] Bernstein D, Fajardo G, Zhao M. The role of β-adrenergic receptors in heart failure: Differential regulation of cardiotoxicity and cardioprotection. Prog Pediatr Cardiol 2011; 31: 35-38.
7. [7] Xiao RP, Ji X, Lakatta EG. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 1995; 47: 322-329.
8. [8] Communal C, Singh K, Sawyer DB, Colucci WS. Opposing Effects of ß1-and ß2-Adrenergic Receptors on Cardiac Myocyte Apoptosis: Role of a Pertussis Toxin-Sensitive G Protein. Circulation 1999; 100: 2210-2212.
9. [9] Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998; 102: 1377-1384.
10. [10] Wahler GMD. Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase. Am J Physiol 1995; 268: C45-54.
11. [11] Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol 2010; 65: 565-570.
12. [12] Wachter SB, Gilbert EM. Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. Cardiology 2012; 122: 104-112.
13. [13] Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol 2011; 8: 369-379.
14. [14] Scicchitano P, Cortese F, Ricci G, Carbonara S, Moncelli M, Iacoviello M, et al. Ivabradine, coronary artery disease, and heart failure: beyond rhythm control. Drug Descov. Developm. Therapy 2014; 8: 689-700.
15. [15] Vilaine JP, Bidouard JP, Lesage L, Reure H, Peglion JL. Antiischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 2003; 42: 688-696.
16. [16] Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, Initiative Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529-2536.
17. [17] Frishman WH, Saunders E. Adrenergic Blockers. J Clin Hypertens (Greenwich) 2011; 13: 649-653.
18. [18] Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet 1990; 336:1-6.
19. [19] Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659-1667.
20. [20] Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999; 96: 7059-7064.
21. [21] Chen-Scarabelli C, Saravolatz II L, Murad Y, Shieh W, Qureshi W, Di Rezze J, et al. A critical review of the use of carvedilol in ischemic heart disease. Am J Cardiovasc Drugs 2012; 12: 391-401.
22. [22] Reiter MJ. Cardiovascular drug class specificity: β-blockers. Prog Cardiovasc Dis 2004; 47: 11-33.
23. [23] Heinicke, G. Propranolol formulations. US20090238869 (2009).
24. [24] Levi, S. Carvedilol phosphate. US20090286845 (2009).
25. [25] Mandaogade, P.M., Joshi, V.M., Srivastava, S., Kadam, V.D., Jain, G.K. Extended release dosage forms of metoprolol. US20110070300 (2011).
26. [26] Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic betareceptor antagonist. Lancet 1964; 1: 1080-1081.
27. [27] Stephen SA. Unwanted effects of propranolol. Am J Cardiol 1966; 18: 463-472.
28. [28] Barrett AM, Carter J, Fitzgerald JD, Hull R, Le Count D. A new type of cardioselective adrenoceptive blocking drug. Br J Pharmacol 1973; 48: 340P.
29. [29] Harry JD, Knapp MF, Linden RJ. The action of ICI-66082 on the heart. Br J Pharmacol 1973; 48: 340P-341P.
30. [30] Hernández-Cañero A, González A, Cardonne A, Pérez-Medina T, Garcia-Barreto D. Effect of atenolol in angina pectoris of effort. Cor Vasa 1972; 20: 99-103.
31. [31] Graham BR, Littlejohns DW, Prichard BN, Scales B, Southorn P. Proceedings: Preliminary observations on the human pharmacology of I.C.I. 66082 in normal volunteers. Br J Pharmacol 1973; 49: 154P-155P.
32. [32] von Möllendorff E, Sponer G, Strein K, Bartsch W, Müller-Beckmann B, Neugebauer G, et al. Carvedilol. Cardiovasc Drug Rev 1987; 5: 135-153.
33. [33] Kaski JC, Rodriguez-Plaza L, Brown J, Maseri A. Efficacy of carvedilol (BM14, 190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. Am J Cardiol 1985; 56: 35-40.
34. [34] Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76-81.
35. [35] Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996; 17: 104-112.
36. [36] Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994; 90: 762-768.
37. [37] Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 1927-1936.
38. [38] Shu DF, Dong BR, Lin XF, Wu TX, Liu GJ. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil. 2011 Apr 27.
39. [Epub ahead of print].
40. [39] Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation 1999; 99: 2829-2848.
41. [40] Bonet S, Agusti A, Arnau JM, Vidal X, Diogene E, Galve E, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000; 160: 621-627.
42. [41] Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308: 1340-1349.
43. [42] Ozasa N, Morimoto T, Bao B, Furukawa Y, Nakagawa Y, Kadota K, et al. β-blocker use in patients after percutaneous coronary interventions: One size fits all? Worse outcomes in patients without myocardial infarction or heart failure. Int J Cardiol 2013; 168: 774-779.
44. [43] Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012; 60: e44-e164.
45. [44] Gottlieb SO, Weisfeldt ML, Ouyang P, Achuff SC, Baughman KL, Traill TA, et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, doubleblind, placebo-controlled trial. Circulation 1986; 73: 331-337.
46. [45] Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol 1987; 60: 18A-25A.
47. [46] Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988; 260: 2259-2263.
48. [47] Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-807.
49. [48] Gundersen T, Abrahamsen AM, Kjekshus J, Ronnevik PK. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group. Circulation 1982; 66: 1179-1184.
50. [49] The beta-blocker heart attack trial. Beta-Blocker Heart Attack Study Group. JAMA 1981; 246: 2073-2074.
51. [50] Hjalmarson A, Herlitz J, Holmberg S, Ryden L, Swedberg K, Vedin A, et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983; 67: I26-32.
52. [51] MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J 1985; 6: 199-226.
53. [52] Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
54. [53] Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60: 1581-1598.
55. [54] First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986; 2: 57-66.
56. [55] Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83: 422-437.
57. [56] Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1998; 32: 634-640.
58. [57] Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1622-1632.
59. [58] Al-Reesi A, Al-Zadjali N, Perry J, Fergusson D, Al-Shamsi M, Al-Thagafi M, et al. Do beta-blockers reduce short-term mortality following acute myocardial infarction? A systematic review and metaanalysis. CJEM 2008; 10: 215-223.
60. [59] Patrick TOG, Frederick GK, Deborah DA, Donald EC, Mina KC James AL, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013; 61: e78-e140.
61. [60] Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013 Oct; 34: 2949-3003.
62. [61] Harjai KJ, Stone GW, Boura J, Grines L, Garcia E, Brodie B, et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocardial infarction. Am J Cardiol 2003; 91: 655-660.
63. [62] Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 2004; 43: 1780-1787.
64. [63] Hirschl MM, Wollmann CG, Erhart F, Brunner W, Pfeffel F, Gattermeier M, et al. Benefit of immediate beta-blocker therapy on mortality in patients with ST-segment elevation myocardial infarction. Crit Care Med 2013; 41: 1396-1404.
65. [64] Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos A, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. Circulation 2013; 128: 1495-1503.
66. [65] Pizarro G, Fernandez-Friera L, Fuster V, Fernandez-Jimenez R, Garcia-Ruiz JM, Garcia-Alvarez A, et al. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). J Am Coll Cardiol 2014; 63: 2356-2362.
67. [66] Park KL, Goldberg RJ, Anderson FA, Lopez-Sendon J, Montalescot G, Brieger D, et al. Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE). Am J Med 2014; 127: 503-511.
68. [67] CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
69. [68] Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients wit heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283: 1295-1302.
70. [69] Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
71. [70] Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.